Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

355

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

April 11, 2025

Study Completion Date

July 5, 2027

Conditions
Giant Cell Arteritis (GCA)
Interventions
BIOLOGICAL

Secukinumab 300 mg

Secukinumab 300 mg

OTHER

Placebo

Placebo

BIOLOGICAL

Secukinumab 150 mg

Secukinumab

Trial Locations (104)

1211

Novartis Investigative Site, Geneva

1346

Novartis Investigative Site, Gjettum

1538

Novartis Investigative Site, Moss

2150

Novartis Investigative Site, Parramatta

2170

Novartis Investigative Site, Liverpool

3000

Novartis Investigative Site, Leuven

3081

Novartis Investigative Site, Heidelberg Heights

3145

Novartis Investigative Site, Malvern East

4000

Novartis Investigative Site, Liège

Novartis Investigative Site, Plovdiv

4002

Novartis Investigative Site, Plovdiv

4031

Novartis Investigative Site, Basel

4032

Novartis Investigative Site, Debrecen

4215

Novartis Investigative Site, Southport

6020

Novartis Investigative Site, Innsbruck

6150

Novartis Investigative Site, Murdoch

6700

Novartis Investigative Site, Esbjerg

6720

Novartis Investigative Site, Szeged

7000

Novartis Investigative Site, Hobart

7623

Novartis Investigative Site, Pécs

8036

Novartis Investigative Site, Graz

8091

Novartis Investigative Site, Zurich

8200

Novartis Investigative Site, Aarhus N

9007

Novartis Investigative Site, Sankt Gallen

10138

Novartis Investigative Site, Tallinn

13008

Novartis Investigative Site, Marseille

13125

Novartis Investigative Site, Berlin

15706

Novartis Investigative Site, Santiago de Compostela

20132

Novartis Investigative Site, Milan

21034

Novartis Investigative Site, Dijon

21740

Osteoporosis and Clinical Trial Ctr, Hagerstown

25123

Novartis Investigative Site, Brescia

28009

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

29200

Novartis Investigative Site, Brest

31008

Novartis Investigative Site, Pamplona

31059

Novartis Investigative Site, Toulouse

33324

IRIS Research and Development, Plantation

34098

Novartis Investigative Site, Istanbul

34239

Sarasota Arthritis Res Ctr, Sarasota

34899

Novartis Investigative Site, Istanbul

38305

West Tennessee Research Institute, Jackson

39008

Novartis Investigative Site, Santander

44093

Novartis Investigative Site, Nantes

44100

Novartis Investigative Site, Cona

44649

Novartis Investigative Site, Herne

46026

Novartis Investigative Site, Valencia

48013

Novartis Investigative Site, Bilbao

50134

Novartis Investigative Site, Florence

50708

Novartis Investigative Site, Tartu

52242

Novartis Investigative Site, Iowa City

University Of Iowa, Iowa City

53100

Novartis Investigative Site, Siena

53105

Novartis Investigative Site, Bonn

59037

Novartis Investigative Site, Lille

67000

Novartis Investigative Site, Strasbourg

67063

Novartis Investigative Site, Ludwigshafen

70100

Novartis Investigative Site, Kuopio

72000

Novartis Investigative Site, Le Mans

75013

Novartis Investigative Site, Paris

75014

Novartis Investigative Site, Paris

76051

Precision Comp Clin Research, Grapevine

77382

Advanced Rheumatology of Houston, Spring

79106

Novartis Investigative Site, Freiburg im Breisgau

90048

Cedars Sinai Medical Center, Los Angeles

91054

Novartis Investigative Site, Erlangen

97080

Novartis Investigative Site, Würzburg

6423906

Novartis Investigative Site, Tel Aviv

02114

Massachusetts General Hospital, Boston

B1900AWT

Novartis Investigative Site, La Plata

C1023AAB

Novartis Investigative Site, Capital Federal

36010 570

Novartis Investigative Site, Juiz de Fora

90035-003

Novartis Investigative Site, Porto Alegre

15090 000

Novartis Investigative Site, São Paulo

H1T 2M4

Novartis Investigative Site, Montreal

J1G 2E8

Novartis Investigative Site, Sherbrooke

G9A 3X2

Novartis Investigative Site, Trois-Rivières

625 00

Novartis Investigative Site, Brno

128 00

Novartis Investigative Site, Prague

148 00

Novartis Investigative Site, Prague

686 01

Novartis Investigative Site, Uherské Hradiště

DK-7100

Novartis Investigative Site, Vejle

00290

Novartis Investigative Site, Helsinki

FIN-15850

Novartis Investigative Site, Lahti

FIN-20520

Novartis Investigative Site, Turku

01307

Novartis Investigative Site, Dresden

01067

Novartis Investigative Site, Dresden

115 27

Novartis Investigative Site, Athens

01010

Novartis Investigative Site, Guatemala City

H-1083

Novartis Investigative Site, Budapest

85 168

Novartis Investigative Site, Bydgoszcz

30-002

Novartis Investigative Site, Krakow

1649-035

Novartis Investigative Site, Lisbon

4990-041

Novartis Investigative Site, Ponte de Lima

08208

Novartis Investigative Site, Sabadell

08916

Novartis Investigative Site, Badalona

08036

Novartis Investigative Site, Barcelona

08041

Novartis Investigative Site, Barcelona

221 85

Novartis Investigative Site, Malmo

06230

Novartis Investigative Site, Ankara

EH4 2XU

Novartis Investigative Site, Edinburgh

ST6 7AG

Novartis Investigative Site, Stoke-on-Trent

DD1 9SY

Novartis Investigative Site, Dundee

NE7 7DN

Novartis Investigative Site, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY